About all

Heparin interactions. Heparin: Uses, Dosage, Side Effects, and Critical Interactions

What are the primary uses of heparin. How is heparin dosage determined. What are the most common side effects of heparin. Which drugs have major interactions with heparin. How does heparin affect patients with certain medical conditions.

Содержание

Understanding Heparin: An Essential Anticoagulant

Heparin is a powerful anticoagulant medication used to prevent and treat blood clots in various medical situations. As a critical component in managing thrombotic disorders, understanding its uses, dosage, side effects, and interactions is essential for healthcare providers and patients alike.

The Therapeutic Applications of Heparin

Heparin plays a crucial role in several medical scenarios. Its primary applications include:

  • Prevention of deep vein thrombosis (DVT) and pulmonary embolism
  • Treatment of acute coronary syndromes
  • Anticoagulation during cardiopulmonary bypass and dialysis
  • Management of disseminated intravascular coagulation (DIC)
  • Prevention of clotting in intravenous lines and catheters

Heparin’s ability to inhibit blood clot formation makes it invaluable in these situations, potentially saving lives and preventing severe complications.

Determining the Correct Heparin Dosage

Heparin dosage is highly individualized and depends on several factors. How is the appropriate dose determined? Healthcare providers consider:

  • Patient’s weight
  • Medical condition being treated
  • Route of administration (intravenous or subcutaneous)
  • Results of blood coagulation tests
  • Patient’s response to the medication

Typically, heparin is administered as a continuous intravenous infusion or intermittent subcutaneous injections. The dosage is carefully monitored and adjusted based on the patient’s activated partial thromboplastin time (aPTT) or anti-Factor Xa levels to ensure optimal anticoagulation while minimizing the risk of bleeding.

Common Side Effects and Precautions

While heparin is an effective medication, it can cause several side effects. What are the most common adverse reactions patients should be aware of?

  • Bleeding (major concern)
  • Bruising or pain at the injection site
  • Thrombocytopenia (low platelet count)
  • Allergic reactions
  • Osteoporosis with long-term use

Healthcare providers must carefully monitor patients for signs of excessive bleeding, which can be life-threatening. Additionally, heparin-induced thrombocytopenia (HIT) is a serious complication that requires immediate attention and discontinuation of heparin therapy.

Critical Drug Interactions with Heparin

Heparin interacts with numerous medications, potentially altering its effectiveness or increasing the risk of side effects. Which drugs have major interactions with heparin?

  • Other anticoagulants (e.g., warfarin, apixaban)
  • Antiplatelet drugs (e.g., clopidogrel, aspirin)
  • Nonsteroidal anti-inflammatory drugs (NSAIDs)
  • Certain antibiotics
  • Thrombolytic agents

These interactions can significantly increase the risk of bleeding or reduce heparin’s anticoagulant effect. Healthcare providers must carefully review a patient’s medication list before initiating heparin therapy and make necessary adjustments to avoid potentially dangerous interactions.

Heparin’s Impact on Specific Medical Conditions

Certain medical conditions can affect how heparin is used or increase the risk of complications. How does heparin affect patients with specific health issues?

  • Peptic ulcer disease: Increased risk of gastrointestinal bleeding
  • Hypertension: Potential for increased bleeding risk
  • Renal dysfunction: May require dose adjustment due to altered drug clearance
  • Liver disease: Can affect heparin metabolism and increase bleeding risk
  • Recent surgery or trauma: Higher risk of bleeding complications

Healthcare providers must carefully assess a patient’s medical history and current condition before prescribing heparin, adjusting the treatment plan as necessary to ensure safety and efficacy.

Monitoring Heparin Therapy: Ensuring Safety and Efficacy

Proper monitoring is crucial for successful heparin therapy. What parameters are typically assessed during treatment?

  • Activated Partial Thromboplastin Time (aPTT)
  • Anti-Factor Xa levels
  • Platelet count
  • Signs of bleeding or thrombosis
  • Liver and kidney function tests

Regular monitoring allows healthcare providers to adjust the heparin dose as needed, ensuring that patients maintain therapeutic anticoagulation levels while minimizing the risk of complications. The frequency of monitoring may vary depending on the clinical situation and individual patient factors.

Special Considerations for Heparin Use in Pregnancy and Breastfeeding

Heparin use during pregnancy and breastfeeding requires careful consideration. How does heparin affect pregnant and nursing women?

  • Pregnancy: Heparin does not cross the placenta, making it the preferred anticoagulant for pregnant women when indicated
  • Risk of osteoporosis with long-term use during pregnancy
  • Potential for increased bleeding risk during delivery
  • Breastfeeding: Heparin is considered safe as it does not pass into breast milk in significant amounts

Healthcare providers must weigh the benefits of heparin therapy against potential risks for pregnant and breastfeeding women, closely monitoring both mother and baby throughout treatment.

Heparin Alternatives and Emerging Therapies

While heparin remains a cornerstone of anticoagulation therapy, several alternatives have emerged in recent years. What are some of the newer anticoagulant options available?

  • Low molecular weight heparins (e.g., enoxaparin)
  • Direct oral anticoagulants (DOACs) such as apixaban, rivaroxaban, and dabigatran
  • Fondaparinux, a synthetic pentasaccharide
  • Bivalirudin, a direct thrombin inhibitor

These alternatives may offer advantages in certain clinical scenarios, such as easier administration or reduced monitoring requirements. However, the choice of anticoagulant depends on various factors, including the specific medical condition, patient characteristics, and potential drug interactions.

Managing Heparin Overdose and Reversal

In cases of heparin overdose or when rapid reversal of anticoagulation is necessary, healthcare providers have specific strategies. How is heparin overdose managed?

  • Administration of protamine sulfate, which neutralizes heparin’s effects
  • Careful monitoring of coagulation parameters
  • Supportive care for any bleeding complications
  • Consideration of additional blood products if severe bleeding occurs

The ability to reverse heparin’s effects quickly is a significant advantage in emergency situations, allowing healthcare providers to manage potentially life-threatening bleeding complications effectively.

Heparin-Induced Thrombocytopenia: A Serious Complication

Heparin-induced thrombocytopenia (HIT) is a rare but potentially severe complication of heparin therapy. What should patients and healthcare providers know about HIT?

  • Typically occurs 5-10 days after starting heparin therapy
  • Characterized by a significant drop in platelet count
  • Can paradoxically increase the risk of thrombosis
  • Requires immediate discontinuation of heparin and transition to alternative anticoagulants
  • May necessitate long-term anticoagulation even after initial resolution

Early recognition and appropriate management of HIT are crucial to prevent potentially life-threatening complications. Healthcare providers must maintain a high index of suspicion and monitor platelet counts regularly in patients receiving heparin therapy.

Advances in Heparin Formulations and Administration

Ongoing research continues to improve heparin therapy and develop new formulations. What recent advancements have been made in heparin administration?

  • Development of synthetic heparin analogues with potentially reduced side effects
  • Exploration of oral heparin formulations to improve patient convenience
  • Investigation of heparin-coated medical devices to prevent thrombosis
  • Refinement of dosing protocols to optimize safety and efficacy
  • Integration of pharmacogenomics to personalize heparin therapy

These advancements aim to enhance the safety, efficacy, and ease of use of heparin therapy, potentially expanding its applications and improving patient outcomes.

Economic Considerations in Heparin Therapy

The cost of heparin therapy can vary significantly depending on various factors. What economic considerations should be taken into account when prescribing heparin?

  • Comparison of costs between unfractionated heparin and low molecular weight heparins
  • Expenses associated with monitoring and dose adjustments
  • Potential cost savings from preventing thrombotic complications
  • Insurance coverage and patient out-of-pocket expenses
  • Long-term economic impact of potential side effects or complications

Healthcare providers and patients must consider these economic factors alongside clinical considerations to ensure optimal and cost-effective anticoagulation therapy.

Patient Education: Key to Successful Heparin Therapy

Proper patient education is crucial for the safe and effective use of heparin. What information should be provided to patients receiving heparin therapy?

  • Importance of adherence to the prescribed dosing regimen
  • Signs and symptoms of bleeding to watch for and report
  • Potential drug and food interactions to avoid
  • Proper technique for self-administration of subcutaneous injections
  • Importance of regular monitoring and follow-up appointments

Empowering patients with knowledge about their heparin therapy can improve compliance, reduce the risk of complications, and enhance overall treatment outcomes.

Future Directions in Anticoagulation Research

The field of anticoagulation continues to evolve, with ongoing research aimed at improving existing therapies and developing novel approaches. What are some potential future directions in anticoagulation research?

  • Development of more selective anticoagulants with reduced bleeding risk
  • Exploration of combination therapies to enhance efficacy and safety
  • Investigation of anticoagulants with reversible effects for better control
  • Personalized anticoagulation strategies based on genetic and clinical factors
  • Integration of artificial intelligence in dosing and monitoring protocols

These research directions hold promise for further improving the management of thrombotic disorders and expanding the therapeutic options available to patients and healthcare providers.

In conclusion, heparin remains a critical component of anticoagulation therapy, with wide-ranging applications in various medical scenarios. Its effectiveness in preventing and treating blood clots is balanced by the need for careful monitoring and management of potential side effects and interactions. As research continues to advance our understanding of anticoagulation, heparin therapy will likely evolve, offering improved safety, efficacy, and convenience for patients requiring anticoagulation.

Heparin Interactions Checker – Drugs.com

Print

Save

There are 224 drugs known to interact with
heparin, along with
7 disease interactions, and 1 alcohol/food interaction.

Of the total drug interactions,
58 are major, 143 are moderate, and 23 are minor.

Does heparin interact with my other drugs?

Enter other medications to view a detailed report.

  • View all 224 medications that may interact with heparin
  • View heparin alcohol/food interactions (1)
  • View heparin disease interactions (7)

Most frequently checked interactions

View interaction reports for heparin and the medicines listed below.

  • Major
  • Moderate
  • Minor
  • Unknown
  • Ativan (lorazepam)
  • Benadryl (diphenhydramine)
  • Cardizem (diltiazem)
  • Colace (docusate)
  • Combivent (albuterol / ipratropium)
  • Coumadin (warfarin)
  • Dilaudid (hydromorphone)
  • Eliquis (apixaban)
  • Lantus (insulin glargine)
  • Lasix (furosemide)
  • Lipitor (atorvastatin)
  • Lopressor (metoprolol)
  • Lovenox (enoxaparin)
  • MiraLAX (polyethylene glycol 3350)
  • Norco (acetaminophen / hydrocodone)
  • Normal Saline Flush (sodium chloride)
  • Norvasc (amlodipine)
  • Paracetamol (acetaminophen)
  • Percocet (acetaminophen / oxycodone)
  • Phenergan (promethazine)
  • Plavix (clopidogrel)
  • Protonix (pantoprazole)
  • Rocephin (ceftriaxone)
  • Synthroid (levothyroxine)
  • Tylenol (acetaminophen)
  • Vitamin B12 (cyanocobalamin)
  • Vitamin C (ascorbic acid)
  • Vitamin D3 (cholecalciferol)
  • Xanax (alprazolam)
  • Zofran (ondansetron)

Heparin alcohol/food interactions

There is 1 alcohol/food interaction with heparin.

Heparin disease interactions

There are 7 disease interactions with heparin which include:

  • peptic ulcer disease
  • active bleeding
  • hypertension
  • prematurity
  • renal dysfunction
  • thrombocytopenia
  • hyperkalemia

Report options

Loading…

QR code containing a link to this page

More about heparin

  • heparin consumer information
  • Compare alternatives
  • Pricing & coupons
  • Reviews (2)
  • Latest FDA alerts (18)
  • Side effects
  • Dosage information
  • Patient tips
  • During pregnancy
  • Drug class: heparins
  • Breastfeeding
  • En español

Related treatment guides

  • Angina
  • Anticoagulation During Pregnancy
  • Antiphospholipid Syndrome
  • Deep Vein Thrombosis

Drug Interaction Classification
These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
MajorHighly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
ModerateModerately clinically significant. Usually avoid combinations; use it only under special circumstances.
MinorMinimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
UnknownNo interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer

Heparin (Porcine) Injection: Uses, Side Effects, Interactions, Pictures, Warnings & Dosing

heparin (porcine) 1,000 unit/mL injection solution

Color: colorlessShape: Imprint:

This medicine is a colorless, clear, vial

heparin (porcine) 1,000 unit/mL injection solution

Color: colorlessShape: Imprint:

This medicine is a colorless, clear, vial

heparin (porcine) 1,000 unit/mL injection solution

Color: clearShape: Imprint:

This medicine is a colorless, clear, vial

heparin (porcine) 1,000 unit/mL injection solution

Color: clearShape: Imprint:

This medicine is a colorless, clear, vial

heparin (porcine) 1,000 unit/mL injection solution

Color: colorlessShape: Imprint:

This medicine is a colorless, clear, vial

heparin (porcine) 5,000 unit/mL injection solution

Color: colorlessShape: Imprint:

This medicine is a colorless, clear, vial

heparin (porcine) 5,000 unit/mL injection solution

Color: clearShape: Imprint:

This medicine is a colorless, clear, vial

heparin (porcine) 1,000 unit/mL injection solution

Color: clearShape: Imprint:

This medicine is a colorless, clear, vial

heparin (porcine) 5,000 unit/mL injection solution

Color: clearShape: Imprint:

This medicine is a colorless, clear, vial

heparin (porcine) 10,000 unit/mL injection solution

Color: colorlessShape: Imprint:

This medicine is a colorless, clear, vial

heparin (porcine) 1,000 unit/mL injection solution

Color: colorlessShape: Imprint:

This medicine is a colorless, clear, vial

heparin (porcine) 1,000 unit/mL injection solution

Color: clearShape: Imprint:

This medicine is a colorless, clear, vial

heparin (porcine) 5,000 unit/mL injection solution

Color: clearShape: Imprint:

This medicine is a colorless, clear, vial

heparin (porcine) 5,000 unit/mL injection solution

Color: colorlessShape: Imprint:

This medicine is a colorless, clear, vial

heparin (porcine) 5,000 unit/mL injection solution

Color: clearShape: Imprint:

This medicine is a colorless, clear, vial

heparin (porcine) 10,000 unit/mL injection solution

Color: colorlessShape: Imprint:

This medicine is a colorless, clear, vial

heparin (porcine) 1,000 unit/mL injection solution

Color: colorlessShape: Imprint:

This medicine is a colorless, clear, vial

heparin (porcine) 5,000 unit/mL injection solution

Color: clearShape: Imprint:

This medicine is a colorless, clear, vial

heparin (porcine) 5,000 unit/mL injection solution

Color: clearShape: Imprint:

This medicine is a colorless, clear, vial

heparin (porcine) 1,000 unit/mL injection solution

Color: clearShape: Imprint:

This medicine is a colorless, clear, vial

heparin (porcine) 1,000 unit/mL injection solution

Color: clearShape: Imprint:

This medicine is a colorless, clear, vial

heparin (porcine) 1,000 unit/mL injection solution

Color: colorlessShape: Imprint:

This medicine is a colorless, clear, vial

heparin (porcine) 5,000 unit/mL injection solution

Color: colorlessShape: Imprint:

This medicine is a colorless, clear, vial

heparin (porcine) 5,000 unit/mL injection solution

Color: Shape: Imprint:

This medicine is a colorless, clear, vial

heparin (porcine) 20,000 unit/mL injection solution

Color: colorlessShape: Imprint:

This medicine is a colorless, clear, vial

heparin (porcine) 20,000 unit/mL injection solution

Color: clearShape: Imprint:

This medicine is a colorless, clear, vial

heparin (porcine) 10,000 unit/mL injection solution

Color: clearShape: Imprint:

This medicine is a colorless, clear, vial

heparin (porcine) 1,000 unit/mL injection solution

Color: clearShape: Imprint:

This medicine is a colorless, clear, vial

heparin (porcine) 5,000 unit/mL injection solution

Color: clearShape: Imprint:

This medicine is a colorless, clear, vial

heparin (porcine) 5,000 unit/mL injection solution

Color: clearShape: Imprint:

This medicine is a colorless, clear, vial

heparin (porcine) 5,000 unit/mL injection solution

Color: colorlessShape: Imprint:

This medicine is a colorless, clear, vial

heparin (porcine) 20,000 unit/mL injection solution

Color: colorlessShape: Imprint:

This medicine is a colorless, clear, vial

heparin (porcine) 10,000 unit/mL injection solution

Color: clearShape: Imprint:

This medicine is a colorless, clear, vial

heparin (porcine) 1,000 unit/mL injection solution

Color: colorlessShape: Imprint:

This medicine is a colorless, clear, vial

heparin (porcine) 10,000 unit/mL injection solution

Color: colorlessShape: Imprint:

This medicine is a colorless, clear, vial

heparin (porcine) 1,000 unit/mL injection solution

Color: clearShape: Imprint:

This medicine is a colorless, clear, vial

heparin (porcine) 1,000 unit/mL injection solution

Color: clearShape: Imprint:

This medicine is a colorless, clear, vial

heparin (porcine) 1,000 unit/mL injection solution

Color: colorlessShape: Imprint:

This medicine is a colorless, clear, vial

heparin (porcine) 5,000 unit/mL injection solution

Color: clearShape: Imprint:

This medicine is a colorless, clear, vial

heparin (porcine) 1,000 unit/mL injection solution

Color: colorlessShape: Imprint:

This medicine is a colorless, clear, vial

heparin (porcine) 5,000 unit/mL (1 mL) injection cartridge

Color: colorlessShape: Imprint:

This medicine is a colorless, clear, vial

heparin (porcine) 10,000 unit/mL injection solution

Color: colorlessShape: Imprint:

This medicine is a colorless, clear, vial

heparin (porcine) 1,000 unit/mL injection solution

Color: colorlessShape: Imprint:

This medicine is a colorless, clear, vial

heparin (porcine) 5,000 unit/mL injection solution

Color: colorlessShape: Imprint:

This medicine is a colorless, clear, vial

heparin (porcine) 1,000 unit/mL injection solution

Color: colorlessShape: Imprint:

This medicine is a colorless, clear, vial

heparin (porcine) 5,000 unit/mL injection solution

Color: colorlessShape: Imprint:

This medicine is a colorless, clear, vial

heparin (porcine) 5,000 unit/mL injection solution

Color: colorlessShape: Imprint:

This medicine is a colorless, clear, vial

heparin (porcine) 20,000 unit/mL injection solution

Color: clearShape: Imprint:

This medicine is a colorless, clear, vial

heparin (porcine) 10,000 unit/mL injection solution

Color: clearShape: Imprint:

This medicine is a colorless, clear, vial

heparin (porcine) 5,000 unit/mL injection solution

Color: clearShape: Imprint:

This medicine is a colorless, clear, vial

heparin (porcine) 1,000 unit/mL injection solution

Color: clearShape: Imprint:

This medicine is a colorless, clear, vial

heparin (porcine) 5,000 unit/mL injection solution

Color: clearShape: Imprint:

This medicine is a colorless, clear, vial

heparin (porcine) 1,000 unit/mL injection solution

Color: colorlessShape: Imprint:

This medicine is a colorless, clear, vial

heparin (porcine) 5,000 unit/mL injection solution

Color: clearShape: Imprint:

This medicine is a colorless, clear, vial

heparin (porcine) 10,000 unit/mL injection solution

Color: clearShape: Imprint:

This medicine is a colorless, clear, vial

heparin (porcine) 1,000 unit/mL injection solution

Color: colorlessShape: Imprint:

This medicine is a colorless, clear, vial

heparin (porcine) 1,000 unit/mL injection solution

Color: colorlessShape: Imprint:

This medicine is a colorless, clear, vial

heparin (porcine) 5,000 unit/mL injection solution

Color: colorlessShape: Imprint:

This medicine is a colorless, clear, vial

heparin (porcine) 5,000 unit/mL injection solution

Color: colorlessShape: Imprint:

This medicine is a colorless, clear, vial

heparin (porcine) 10,000 unit/mL injection solution

Color: colorlessShape: Imprint:

This medicine is a colorless, clear, vial

heparin (porcine) 5,000 unit/mL injection solution

Color: colorlessShape: Imprint:

This medicine is a colorless, clear, vial

heparin (porcine) 1,000 unit/mL injection solution

Color: colorlessShape: Imprint:

This medicine is a colorless, clear, vial

heparin (porcine) 1,000 unit/mL injection solution

Color: colorlessShape: Imprint:

This medicine is a colorless, clear, vial

heparin (porcine) 1,000 unit/mL injection solution

Color: colorlessShape: Imprint:

This medicine is a colorless, clear, vial

heparin (porcine) 5,000 unit/mL injection solution

Color: colorlessShape: Imprint:

This medicine is a colorless, clear, vial

heparin (porcine) 1,000 unit/mL injection solution

Color: colorlessShape: Imprint:

This medicine is a colorless, clear, vial

heparin (porcine) 5,000 unit/mL injection solution

Color: clearShape: Imprint:

This medicine is a colorless, clear, vial

heparin (porcine) 5,000 unit/mL injection solution

Color: clearShape: Imprint:

This medicine is a colorless, clear, vial

heparin (porcine) 10,000 unit/mL injection solution

Color: colorlessShape: Imprint:

This medicine is a colorless, clear, vial

heparin (porcine) 1,000 unit/mL injection solution

Color: colorlessShape: Imprint:

This medicine is a colorless, clear, vial

heparin (porcine) 1,000 unit/mL injection solution

Color: colorlessShape: Imprint:

This medicine is a colorless, clear, vial

heparin (porcine) 1,000 unit/mL injection solution

Color: colorlessShape: Imprint:

This medicine is a colorless, clear, vial

heparin (porcine) 1,000 unit/mL injection solution

Color: colorlessShape: Imprint:

This medicine is a colorless, clear, vial

heparin (porcine) 5,000 unit/mL (1 mL) injection cartridge

Color: colorlessShape: Imprint:

This medicine is a colorless, clear, vial

Heparin sodium drug interactions with other drugs (compatibility) | Vidal.

ru

Heparin sodium drug interactions with other drugs (compatibility) | Vidal.ru – a directory of medicines

Effects when used simultaneously with drugs
Abciximab Risk of bleeding. With simultaneous use, monitoring of the APTT is required.
Oral anticoagulants (vitamin K antagonists) Concomitant use of oral anticoagulants and low molecular weight heparins increases the risk of bleeding due to the additive anticoagulant effect. Both heparin and warfarin prolong the aPTT and prothrombin time. This disorder is recommended to be considered taking into account the therapeutic effect, since normal coagulation values ​​do not reflect the risk of bleeding. To reduce distortion in the determination of prothrombin time due to bolus intravenous heparin, an interval of at least 5-6 hours should be observed between the last administration of heparin and blood sampling.
NSAIDs Risk of hemorrhagic complications due to simultaneous inhibition of blood coagulation and platelet aggregation. If simultaneous use cannot be avoided, then constant monitoring of the patient’s condition is required.
Dextran Increased risk of bleeding due to antithrombotic and antiplatelet properties of dextran. The combination should be avoided unless the potential benefit of therapy outweighs the risk of bleeding, in which case an appropriate dose reduction of heparin is required.
Probenecid May increase the effects of heparin under the influence of probenecid and the development of bleeding.
Salicylates It has been established that the use of acetylsalicylic acid during heparin therapy increases the risk of bleeding by 2. 5 times. Due to antiplatelet and antithrombotic properties, salicylates can potentiate the anticoagulant effect of heparin, which increases the risk of bleeding. In addition, the ulcerogenic effect of salicylates may increase the risk of bleeding from the gastrointestinal tract. The use of this combination is characterized by a high risk, therefore, if combination therapy is necessary, the expected benefit and potential risk should be carefully evaluated. If combined use is necessary, then constant monitoring of the patient’s condition is required.

Our website uses cookies to improve your user experience and performance, as well as marketing activities.
By continuing, you agree to the use of cookies.
Ok

Order a drug

Heparin instructions for use: indications, contraindications, side effects – description of Heparin solution for injections.

5 thousand IU / ml: 1 ml or 2 ml amp. 5 or 10 pieces, 5 ml vial 5 or 50 pcs. (4363)

💊 Composition of the drug Heparin

✅ Use of the drug Heparin

Save

Search for analogues

Interaction

Description of the active ingredients of the preparation

Heparin
(Heparin)

The scientific information provided is general and cannot be used to make decisions.
decisions about the use of a particular drug.

Update date: 2019.12.04

Marketing authorization holder:

SYNTHESIS JSC
(Russia)

ATX code:

B01AB01

(Heparin)

Active substance:
sodium heparin
(heparin sodium)

Rec. INN

WHO registered

Dosage form

Heparin

Injection solution 5 thousand IU / ml: 1 ml or 2 ml amp. 5 or 10 pieces, 5 ml vial 5 or 50 pcs.

reg. No.: R N000116/01
dated 01.10.07
– Indefinitely

Release form, packaging and composition
drug Heparin

5 ml – bottles (5) – packs of cardboard.
5 ml – bottles (50) – cardboard boxes.
5 ml vials.
5 ml – bottles (5) – contour plastic packaging (1) – packs of cardboard.
1 ml – ampoules (5) – blister strip packs (2) – cardboard packs.
2 ml – ampoules (5) – blister strip packs (1) – cardboard packs.
5 ml – ampoules (5) – blister strip packs (1) – cardboard packs.
5 ml – ampoules (5) – blister strip packs (2) – cardboard packs.
2 ml – ampoules (5) – blister strip packs (2) – cardboard packs.
1 ml – ampoules (5) – blister packs (1) – cardboard packs.

Clinical and pharmacological group:

Direct acting anticoagulant – medium molecular weight heparin

Pharmacotherapeutic group:

Direct acting anticoagulant

Pharmacological action

Direct acting anticoagulant belongs to the group of medium molecular weight heparins. In blood plasma, it activates antithrombin III, accelerating its anticoagulant effect. Violates the transition of prothrombin to thrombin, inhibits the activity of thrombin and activated factor X, to some extent reduces platelet aggregation.

For unfractionated standard heparin, the ratio of antiplatelet activity (anti-factor Xa) to anticoagulant activity (APTT) is 1:1.

Increases renal blood flow; increases the resistance of cerebral vessels, reduces the activity of cerebral hyaluronidase, activates lipoprotein lipase and has a hypolipidemic effect. Reduces the activity of surfactant in the lungs, suppresses excessive synthesis of aldosterone in the adrenal cortex, binds adrenaline, modulates the ovarian response to hormonal stimuli, enhances the activity of parathyroid hormone. As a result of interaction with enzymes, it can increase the activity of brain tyrosine hydroxylase, pepsinogen, DNA polymerase and reduce the activity of myosin ATPase, pyruvate kinase, RNA polymerase, pepsin.

Heparin has been shown to have immunosuppressive activity.

In patients with coronary artery disease (in combination with acetylsalicylic acid) reduces the risk of acute coronary artery thrombosis, myocardial infarction and sudden death. Reduces the frequency of recurrent heart attacks and mortality in patients with myocardial infarction. In high doses, it is effective for pulmonary embolism and venous thrombosis, in small doses it is effective for the prevention of venous thromboembolism, incl. after surgical operations.

With intravenous administration, blood coagulation slows down almost immediately, with intramuscular injection – after 15-30 minutes, with s / c – after 20-60 minutes, after inhalation, the maximum effect is after a day; the duration of the anticoagulant action, respectively, is 4-5, 6, 8 hours and 1-2 weeks, the therapeutic effect – prevention of thrombosis – lasts much longer. Deficiency of antithrombin III in plasma or at the site of thrombosis may reduce the antithrombotic effect of heparin.

Pharmacokinetics

After subcutaneous administration C max of the active substance in plasma is observed after 3-4 hours. Heparin does not penetrate the placenta well due to its large molecular weight. Not excreted in breast milk.

T 1/2 from plasma is 30-60 min.

Indications of the active substances of the drug

Heparin

Prevention and therapy: deep vein thrombosis, pulmonary embolism (including in peripheral vein diseases), coronary artery thrombosis, thrombophlebitis, unstable angina, acute myocardial infarction, atrial fibrillation (including accompanied by embolism), DIC, prevention and therapy of microthrombosis and microcirculation disorders, renal vein thrombosis, hemolytic uremic syndrome, mitral heart disease (thrombosis prevention), bacterial endocarditis, glomerulonephritis, lupus nephritis.

Prevention of blood coagulation during operations using extracorporeal methods of circulation, during hemodialysis, hemosorption, peritoneal dialysis, cytapheresis, forced diuresis, when washing venous catheters.

Preparation of non-clotting blood samples for laboratory purposes and blood transfusion.

Open list of ICD-10 codes

D59.3 Hemolytic uremic syndrome
D65 Disseminated intravascular coagulation [defibrination syndrome]
I20.0 Unstable angina
I21 Acute myocardial infarction
I26 Pulmonary embolism
I33.9 Acute endocarditis, unspecified
I34. 0 Mitral (valvular) insufficiency
I48 Atrial fibrillation and flutter
I74 Arterial embolism and thrombosis
I80 Phlebitis and thrombophlebitis
I82 Embolism and thrombosis of other veins
N00 Acute nephritic syndrome (acute glomerulonephritis)
N03 Chronic nephritic syndrome
N08.5 Glomerular lesions in systemic connective tissue diseases
Z51.4 Preparatory procedures for subsequent treatment or examination, not elsewhere classified

Dosing regimen

The method of administration and dosing regimen of a particular drug depends on its form of release and other factors. The optimal dosage regimen is determined by the doctor. Compliance of the dosage form of a particular drug with indications for use and dosing regimen should be strictly observed.

Individual, depending on the dosage form used, indications, clinical situation and age of the patient.

Side effects

On the part of the blood coagulation system: possible bleeding of the gastrointestinal tract and urinary tract, bleeding at the injection site, in areas subjected to pressure, from surgical wounds, as well as hemorrhages in other organs, hematuria, thrombocytopenia.

From the digestive system: nausea, loss of appetite, vomiting, diarrhea, increased activity of liver transaminases.

Allergic reactions: flushing of the skin, drug fever, urticaria, rhinitis, pruritus and sensation of heat in the soles, bronchospasm, collapse, anaphylactic shock.

On the part of the blood coagulation system: thrombocytopenia (may be severe up to death) with subsequent development of skin necrosis, arterial thrombosis, accompanied by the development of gangrene, myocardial infarction, stroke.

From the musculoskeletal system: with prolonged use – osteoporosis, spontaneous fractures, soft tissue calcification.

Local reactions: irritation, pain, hyperemia, hematoma and ulceration at the injection site.

Other: transient alopecia, hypoaldosteronism.

Contraindications for use

Bleeding, diseases accompanied by impaired blood coagulation, suspected intracranial hemorrhage, cerebral aneurysm, hemorrhagic stroke, dissecting aortic aneurysm, antiphospholipid syndrome, malignant arterial hypertension, subacute bacterial endocarditis, erosive ulcerative lesions of the gastrointestinal tract , severe lesions of the liver parenchyma, cirrhosis of the liver with varicose veins of the esophagus, malignant neoplasms in the liver, shock conditions, recent surgical interventions on the eyes, brain, prostate, liver and biliary tract, condition after spinal cord puncture, menstruation, threatened miscarriage, childbirth (including recent), hypersensitivity to heparin.

Use during pregnancy and lactation

Use during pregnancy is possible only under strict indications, under close medical supervision.

Contraindication: threatened miscarriage, childbirth (including recent).

Can be used during breastfeeding if indicated.

Use for violations of liver function

Contraindications: severe lesions of the liver parenchyma, cirrhosis of the liver with varicose veins of the esophagus, malignant neoplasms in the liver.

Use for impaired renal function

Used when indicated in patients with severe kidney disease.

Use in children

May be used in children if indicated.

Use in elderly patients

Use with caution in elderly patients (over 60 years, especially in women).

Special instructions

Use with caution in patients suffering from polyvalent allergies (including bronchial asthma), arterial hypertension, dental procedures, diabetes mellitus, endocarditis, pericarditis, in the presence of an intrauterine contraceptive, with active tuberculosis, radiation therapy, liver failure, chronic renal failure, in elderly patients (over 60 years, especially women).

IM administration of heparin is not recommended due to the possibility of developing a hematoma, as well as IM administration of other drugs during treatment with heparin.

Use with caution externally for bleeding and conditions of increased bleeding, thrombocytopenia.

During treatment with heparin, monitoring of blood coagulation parameters is necessary.

Only normal saline is used to dilute heparin.

With the development of severe thrombocytopenia (a decrease in the number of platelets by 2 times from the original number or below 100,000 / µl), heparin should be urgently discontinued.

The risk of bleeding can be minimized with careful evaluation of contraindications, regular laboratory monitoring of blood clotting, and adequate dosing.

Drug interactions

The anticoagulant effect of heparin is enhanced by the simultaneous use of anticoagulants, antiplatelet agents and NSAIDs.

Ergot alkaloids, thyroxine, tetracycline, antihistamines, and nicotine reduce the effect of heparin.

Leave a Reply

Your email address will not be published. Required fields are marked *